All In Biotech

Drug Trial Radar · NCT05682378

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

An Open-label, Single Arm, Multicenter Extension Study to Evaluate Long-term Safety and Tolerability of Inclisiran in Participants With Heterozygous or Homozygous Familial Hypercholesterolemia Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20 or ORION-19 Studies (VICTORION-PEDS-OLE)

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

195

Planned (sponsor's estimate)

Start

Feb 10, 2023

Primary completion

Mar 25, 2032

Study completion Mar 28, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH who have completed the ORION-16 (CKJX839C12301), ORION-13 (CKJX839C12302), ORION-20 (CKJX839C12303) or ORION-19 (CKJX839C12304) studies.

Conditions

  • Heterozygous or Homozygous Familial Hypercholesterolemia

Interventions

  • InclisiranDrug

    Solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs)Time frame: From Day 1 in the study up to the end of study visit; up to 1080 days

Locations

52 sites in 26 countries. Site status is shown where the registry gives one.

  • Excel Medical Clinical Trials LLC

    Boca Raton, Florida · Completed

  • Icahn School of Med at Mt Sinai

    New York, New York · Active not recruiting

  • Cincinnati Childrens Hospital MC

    Cincinnati, Ohio · Completed

  • Childrens Hosp Pittsburgh UPMC

    Pittsburgh, Pennsylvania · Completed

  • Primary Childrens Medical Center

    Salt Lake City, Utah · Recruiting

  • Novartis Investigative Site

    Formosa, Formosa Province, Argentina · Active not recruiting

  • Novartis Investigative Site

    Fortaleza, Ceará, Brazil · Active not recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Completed

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Active not recruiting

  • Novartis Investigative Site

    Québec, Quebec, Canada · Active not recruiting

  • Novartis Investigative Site

    Prague, Czechia · Active not recruiting

  • Novartis Investigative Site

    Prague, Czechia · Active not recruiting

  • Novartis Investigative Site

    Besançon, France · Active not recruiting

  • Novartis Investigative Site

    Toulouse, France · Active not recruiting

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany · Completed

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, Germany · Active not recruiting

  • Novartis Investigative Site

    Athens, Greece · Completed

  • Novartis Investigative Site

    Athens, Greece · Active not recruiting

  • Novartis Investigative Site

    Pécs, Baranya, Hungary · Completed

  • Novartis Investigative Site

    Jerusalem, Israel · Active not recruiting

  • Novartis Investigative Site

    Ramat Gan, Israel · Active not recruiting

  • Novartis Investigative Site

    Milan, MI, Italy · Completed

  • Novartis Investigative Site

    Modena, MO, Italy · Completed

  • Novartis Investigative Site

    Roma, RM, Italy · Completed

  • Novartis Investigative Site

    Roma, RM, Italy · Active not recruiting

  • Novartis Investigative Site

    Irbid, Jordan · Active not recruiting

  • Novartis Investigative Site

    Beirut, Lebanon · Active not recruiting

  • Novartis Investigative Site

    Beirut, Lebanon · Active not recruiting

  • Novartis Investigative Site

    Kuala Lumpur, Malaysia · Active not recruiting

  • Novartis Investigative Site

    Sungai Buloh, Selangor, Malaysia · Active not recruiting

  • Novartis Investigative Site

    Amsterdam, North Holland, Netherlands · Active not recruiting

  • Novartis Investigative Site

    Rotterdam, South Holland, Netherlands · Active not recruiting

  • Novartis Investigative Site

    Oslo, Norway · Active not recruiting

  • Novartis Investigative Site

    Gdansk, Poland · Active not recruiting

  • Novartis Investigative Site

    Lodz, Łódź Voivodeship, Poland · Completed

  • Novartis Investigative Site

    Kemerovo, Russia · Completed

  • Novartis Investigative Site

    Moscow, Russia · Completed

  • Novartis Investigative Site

    Poprad, Slovakia · Active not recruiting

  • Novartis Investigative Site

    Ljubljana, Slovenia · Active not recruiting

  • Novartis Investigative Site

    Bloemfontein, Free State, South Africa · Active not recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.